About the IBBL

The Integrated BioBank of Luxembourg (IBBL) is an independent, not-for-profit biobanking and biotechnology foundation designed to facilitate new, high quality medical research in Luxembourg and to bring the next generation of healthcare to its citizens.

 

The IBBL collects, stores, and analyses biological samples and associated data, which are then made available to research organisations investigating new treatments for diseases. Biobanks like the IBBL play a critical role in modern medical research by allowing researchers to improve our understanding of diseases and identify suitable treatments.

An integrated biobank offering biospecimens, data, technologies and driving research

 

The IBBL has built an integrated and solid infrastructure to support a successful biomedical research industry in Luxembourg and facilitate rapid translation of discoveries into improved care :  

  • A Biospecimen Collection and Biorepository that contains high quality tissues and maintains strong quality control of the specimens and the clinical data associated with the tissue samples, while maintaing the highest biobanking ethical standards.
  • A Biorefinery Analysis and Research service that can make high quality analytes from tissues (e.g. DNA, RNA and protein), maintains technology for high throughput gene sequencing and gene experssion, and conducts biospecimen research.
  • An Informatics Platform to maintain the clinical and biospecimens data in a secure fashion to guarantee the privacy of individual data and to provide data to the bioinformatics hub at the Luxembourg Centre for Systems Biomedicine (LCSB) for additional analysis.

Supporting the Luxembourg Personalized Medicine initiative

 

The IBBL supports the Luxembourg Personalized Medicine Consortium (PMC) and its partners by collecting, storing and redistributing biospecimens and their related clinical data, which are suitable for analyses by state-of-the-art genomics and proteomics platforms used in personalized medicine research.

 

The IBBL works closely with the research teams of the PMC's four major research programmes in personalized medicine (cancer, type 2 diabetes, Parkinson's Disease and normal population cohort) by providing them with biospecimens and clinical data and by analyzing biospecimens using sophisticated molecular analyses that are not feasible in individual research laboratories.